Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by ELISA for anti-pseudomonas LPS IgG antibodies |
| |
| Affiliation: | 1. Bacteriology Department, University of Edinburgh Medical School, Edinburgh, Scotland, UK;2. Regional Blood Transfusion Centre, Royal Infirmary, Edinburgh, Scotland, UK;3. Department of Transfusion Medicine, Royal Infirmary, Edinburgh, Scotland, UK;1. Department of Chemical and Process Systems Engineering, Faculty of Engineering and Technology, Harare Institute of Technology, P. O. Box BE 277, Belvedere, Harare, Zimbabwe.;2. Department of Physics and Nanotechnology, Faculty of Engineering and Technology, SRM University, Kattankulathur, Chennai – 603 203, India;1. Independent Public Health Care Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre, Olsztyn, Poland;2. Maria Sklodowska-Curie Memorial Oncology Center and Institute of Oncology, Warsaw, Poland;3. Centre of Oncological Diagnostics and Therapy, Tomaszów Mazowiecki, Poland;4. Department of Radiotherapy, Medical University of Lodz, Poland;1. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO;2. Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO;3. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO;1. Department of Mathematics, University of Rochester, Rochester, NY 14627, United States;2. Serbian Academy of Sciences and Arts, Knez Mihailova 35, 11000 Beograd, Serbia;1. Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland;2. Institute for Physical Science and Technology, University of Maryland, College Park, Maryland;3. National Institutes of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland;1. Global Health Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), Station 19, CH-1015 Lausanne, Switzerland;2. Department of Biochemistry, University of Geneva, 30 quai E. Ansermet, 1211-Geneva-4, Switzerland |
| |
| Abstract: | An enzyme-linked immunosorbant assay (ELISA) with urease enzyme was developed with either a polyvalent pseudomonas smooth lipopolysaccharide (LPS) extract vaccine (PEV-02) or rough LPS (R-LPS) from P. aeruginosa rough mutant PAC605. Each ELISA was able to differentiate between sera from cystic fibrosis (CF) patients chronically colonized with P. aeruginosa and sera from non-colonized patients. Sera from non-colonized and intermittently colonized CF patients seldom reacted with any of the Pseudomonas LPS, whereas sera from chronically colonized CF patients reacted strongly with most of the sixteen smooth O-serotype vaccine components and with the PAC605 R-LPS, indicating the presence either of a number of different serotype specific IgG antibodies and/or IgG antibodies directed to a common antigenic component of LPS rough core. Absorption studies and immunoblot analysis demonstrated that in sera from CF patients who were chronically colonized with P. aeruginosa a significant component of the anti-P. aeruginosa antibodies is specific for the core of P. aeruginosa LPS and cross reactive with a number of serotypes of P. aeruginosa LPS. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
